Background: Patients with KEAP1 and STK11 alterations have shown poor response to immunotherapy in non-small cell lung cancer (NSCLC) due to unknown underlying mechanisms. In a sub-study of the TNM-I trial (NCT03299478), we discovered that lung adenocarcinomas (LUAD) with concurrent KEAP1 and STK11 mutations exhibit predominantly non-inflamed immunological features, potentially contributing to ...